Navigation Links
SomaLogic and New England Biolabs announce agreement to use SOMAmers for multiple PCR products
Date:7/27/2011

Boulder, CO and Ipswich, MA (July 27, 2011) SomaLogic, Inc. and New England Biolabs, Inc. (NEB) announce today that they have entered into an exclusive licensing agreement whereby SomaLogic will provide specific SOMAmers as critical and unique reagents in several current and future NEB nucleic acid amplification and polymerase chain reaction (PCR) products.

SOMAmers are specific protein binding reagents based on chemically modified "aptamers," or short single-stranded nucleic acids. Although SOMAmers have nearly unlimited potential in many different proteomic applications (e.g., biomarker discovery and validation, clinical diagnostics, drug discovery and development), NEB is incorporating specific SOMAmers into their products as reversible inhibitors of thermally active DNA polymerases used in PCR (e.g., NEB's OneTaqTM Hot Start DNA Polymerase).

"We are delighted that our colleagues at New England Biolabs see the utility of SOMAmers in enhancing and differentiating their outstanding laboratory solutions from their many competitors," said Nebojsa Janjic, Chief Science Officer of SomaLogic. "We look forward to working with them to further explore and apply the distinct advantages of our powerful technology in research laboratory settings."

"There are many opportunities to further enhance the performance of thermally active DNA polymerases in PCR reactions," states Dr. Salvatore Russello, Associate Director of Business Development at NEB. "This agreement is thus of great value to NEB, and is already being used to improve the application of DNA polymerases, such as OneTaq Hot Start."

Terms of the agreement were not disclosed.


'/>"/>

Contact: Fintan Steele, Ph.D.
fsteele@somalogic.com
SomaLogic, Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
2. Study: Illegal fishing harming present and future New England groundfish fisheries
3. Data published in the New England Journal of Medicine support use of raxibacumab (ABthrax) for the treatment of inhalation anthrax
4. LSUHSCs England plays key role in developing new ALS treatment guidelines
5. Researchers issue outlook for a significant New England red tide in 2010
6. Researchers discover potential solutions to New England roadside erosion
7. A major prize in the chemical sciences announced by the Camille and Henry Dreyfus Foundation
8. 2008 SNM Wagner-Torizuka Fellowships announced
9. NIAID announces 25 new awards to develop radiation countermeasures
10. Aware Announces Q3 2008 Earnings Conference Call
11. Governor Doyle announces historic genomic research collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: